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Type 1 diabetes of man and animal models results from immune-mediated specific beta cell destruction.
Multiple islet antigens are targets of autoimmunity and most of these are not beta cell specific. Immune
responses to insulin appear to be essential for the development of diabetes of the NODmouse. In this review,
we will emphasize the unusual manner in which selected autoantigenic peptides (particularly the recently
discovered target of BDC2.5 T cells [chromagranin A]) are presented and recognized by autoreactive CD4+
T cell receptors. We hypothesize that ‘‘unusual’’ structural interactions of specific trimolecular complexes
(MHC class II, peptide, and T cell receptors) are fundamental to the escape from the thymus of autoreactive
T cells able to cause type 1 diabetes.Introduction
Type 1 diabetes (T1D) is presumed to result from T cell-mediated
destruction of the pancreatic islet b cells that secrete insulin.
Immune-mediated diabetes (type 1A) is predictable in man and
preventable in animal models, but not yet safely prevented in
man. Presently prediction of disease relies primarily upon the
observation that individuals expressing specific autoantibodies
reacting withR2 of 4 well-defined autoantigens (insulin, GAD65
[glutamic acid decarboxylase], IA-2 [insulinoma antigen], and
ZnT8 [islet zinc transporter]) essentially always progress to dia-
betes. In young children, diabetes can occur within months of
the appearance of autoantibodies, but diabetes in some children
will take more than a decade to progress, with evidence of
chronic beta cell destruction preceding diabetes over years.
The appearance of autoantibodies is acute and during the predi-
abetic period different autoantibodies rise and fall, but usually
more than two are expressed, sometimes for decades. Similar
to man, the NOD (nonobese diabetic) mouse model develops
insulin autoantibodies, although detection of other autoanti-
bodies has been more difficult when measured with highly
specific assays. Alternatively, T cell-mediated autoimmunity to
multiple autoantigens is better characterized in the NOD mouse
model than in man.
In mouse and humans, the B cell and T cell antigen targets of
TID are overlapping, but not identical. For example, in both
species insulin has been shown to be both a B cell and T cell
target. In man, ZnT8 is a B cell target (Wenzlau et al., 2007),
but not yet described as a T cell target, Alternatively, in mice
chromogranin A (Chga) has been shown to be a T cell target
(Stadinski et al., 2010), but autoantibodies specific for this protein
have not been described. Fundamental molecular questions
remain as towhy certain antigens and certain epitopes of specific
antigens are predominantly targeted in man and animal models.
Are there primary target epitopes driving the autoimmune
process and to what extent is targeting of multiple antigens
necessary for disease?Finally,what locks in thedestructive auto-
immune process that ultimately gives rise to clinical disease?
We will emphasize the hypothesis that underlying susceptibility
may relate to the manner in which specific peptides are pre-
sented to the immune system by polymorphic MHC (major histo-446 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.compatibility complex) class II molecules and recognized by
T cells that escape thymic tolerance. These molecular interac-
tions may control the propensity for b-cell specific destruction,
whereas many other immunologic pathways (and genes) may
contribute to the heightened risk of multiple diabetes-associated
autoimmune disorders seen in man and animal models.
Pathogenesis of Type 1 Diabetes: The Central Role
of T Cells
There is considerable data that chronic autoimmunity underlies
the progression to diabetes in man and multiple spontaneous
animal models. Once autoimmunity appears in man (evidenced
by islet autoantibodies and progressive loss of insulin secretion)
decades can elapse before the appearance of hyperglycemia.
In the NODmouse, insulitis precedes diabetes usually bymonths
and a subset of mice with insulitis will never progress to overt
disease. In the BB rat (BioBreeding) model, there is less vari-
ability with a relatively acute progression to hyperglycemia after
insulitis.
In all three cases, invasion by T cell lymphocytes and destruc-
tion of beta cells among individual islets are asynchronous
(Gepts and Lecompte, 1981; Miyazaki et al., 1985) (Hanenberg
et al., 1989). Pseudoatrophic islets, lacking all b-cells, but con-
taining all other endocrine cells (e.g., those producing glucagon,
somatostatin, and/or pancreatic polypeptide) are considered the
end product of islet autoimmunity and no longer have T cell infil-
trates. These end product islets exist in the same pancreas with
normal islets, as well as islets showing peri- and/or intra-islet
T cell invasion. Recent studies of nPOD program pancreas
(pancreas from cadaveric donors with long-term Type 1 dia-
betes) illustrate that the destructive process is often lobular
with regions where all islets retain b-cells. Thus, large areas of
the pancreas will have pseudoatrophic islets, juxtaposed with
areas of b-cell containing islets that appear relatively normal.
However, even these areas are not normal with b-cell expression
of the molecule survivin (survivin is expressed normally only in
fetal b-cells) and hyperexpression of MHC class I molecules
(Gianani et al., 2010). It is likely this lobular asynchronous
destruction of islet beta cells underlies the chronic natural history
of progression to diabetes.
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numerous experiments have been conducted to dissect which
components of the infiltrate are required for the development
of disease. By far, T cells have been the one immune cell
population that has consistently been shown to be critical for
disease pathogenesis. T cells are known to infiltrate the islets
in both rodent models of disease (NOD and BB) and constitute
a substantial fraction of infiltration observed in humans (Miyazaki
et al., 1985; Gepts and Lecompte, 1981). Removal or the com-
plete absence of mature T cells in the two rodent models
prevents diabetes (Ogawa et al., 1985; Like et al., 1982; Like
et al., 1986; Ikehara et al., 1985; Christianson et al., 1993), and
prolonged b-cell function is observed in recent onset patients
treated with a CD3 antibody (Herold et al., 2002; Keymeulen
et al., 2005). Likewise, adoptive transfer of T cells alone in rodent
models can cause the development of disease (Christianson
et al., 1993; Whalen et al., 1994). The pathogenic process is
largely believed to be dependent upon the presence of autoreac-
tive CD8+ and CD4+ T cell subsets. It is thought that CD8+ T cells
may be more important during the early phases of pathogenesis
(DiLorenzo et al., 1998; Groen et al., 2003), whereas CD4+ T cells
are required throughout. This suggests that there is an evolution
in the pathogenic T cell response during the course of disease.
Furthermore, individual islet-responsive CD4+ and CD8+ T cell
clones have been isolated from diabetic animals that can either
directly mediate or greatly accelerate b-cell destruction (Pakala
et al., 1997; Haskins and McDuffie, 1990; Daniel et al., 1995;
Wong et al., 1996). Collectively, these findings have reinforced
the notion that T cells play an integral role in the development
of T1D.
Although T cells have been the main focus of the T1D field,
they are not the only components of the autoimmune response
believed to play a role in disease pathogenesis. NOD mice defi-
cient in B lymphocytes, but displaying normal numbers of T cells,
are prevented from developing disease (Serreze et al., 1996).
Treatment of both man (Pescovitz et al., 2009) and NOD mice
displaying the human CD20 molecule (Hu et al., 2007) with a B
cell-specific anti-CD20 antibody alters progression to diabetes,
again demonstrating the importance of B cell lymphocytes, but
not directly proving a role for pathogenic autoantibodies. The
lack of diabetes in infants of mothers expressing anti-islet auto-
antibodies argues against a direct role for autoantibodies, but
there is evidence from the NOD mouse model that maternally
transferred autoantibodies are essential (Greeley et al., 2002).
In addition, macrophages are among first populations of immune
cells to infiltrate the islets and are also believed to contribute to
pathogenesis (Hanenberg et al., 1989; Yoon et al., 1998; Jarpe
et al., 1990–1991). It is possible that autoreactive B cells play
an indirect role in disease progression by serving as antigen-
presenting cells for pathogenic T cells. Therefore, while it is
unclear which events initiate autoimmunity and the interplay of
the entire immune response to the pathogenic process, there
has been steady progress in identifying the self-antigen targets
of autoantibodies andmore recently self-antigen targets of path-
ogenic T cells.
Self-Antigen Targets in Type 1 Diabetes
The majority of self-antigen targets have been defined through
the presence of serum autoantibodies. Others have been identi-fied with b-cell-reactive T cell clones isolated from the pancreas
or pancreatic lymph nodes. Specific autoantibodies have been
useful in following the progression to T1D in mouse and humans.
Work to define the relative contribution of CD4+ and CD8+ T cells
that target particular autoantigens has made significant pro-
gress recently. A systematic overview of identified self-antigens
targets has been the focus of previous reviews (Lieberman and
DiLorenzo, 2003) and will not be discussed here in detail. The
growing list of target antigens includes insulin, as well as gluta-
mic acid decarboxylase (GAD), insulinoma antigen-2 (IA-2),
phogrin (IA-2b), and islet-specific glucose-6-phosphatase cata-
lytic subunit related protein (IGRP). In this section, we will give
some background on insulin and two new autoantigens: one
recently identified as a prominent target of autoantibodies in
T1D patients (Wenzlau et al., 2007) and one as the target of highly
pathogenic CD4+ T cells from the NOD mouse (Stadinski et al.,
2010). In subsequent sections, we will discuss in some detail
the T cells specific for various antigens, their relative importance
in T1D pathology, and the nature of the epitopes they recognize.
Insulin is a major target of both B cells and T cells in T1D in mice
and humans. Approximately one-third of the proteins within
islets consist of insulin packaged in a crystalline form and com-
plexed with zinc in secretory granules. Palmer and coworkers
first demonstrated the presence of insulin autoantibodies prior
to insulin therapy in man. The autoantibodies of man recognize
a limited conformational determinant (Figure 1) centered on
A13 leucine (Castan˜o et al., 1993) and requiring both the A and
B chain of insulin such that binding of insulin to standard
ELISA plates obscures this key epitope of prediabetic insulin
autoantibodies (but not insulin antibodies after subcutaneous
insulin injections). The autoantibodies of the NOD mouse are
different and can react with insulin bound to plates. Insulin auto-
antibodies are usually, but not always, the first autoantibody to
appear in young children developing diabetes. The amounts of
insulin autoantibodies inversely correlate with the age at which
diabetes develops, and after age 12 only a minority of new-onset
diabetics expresses detectable insulin autoantibodies. When
first detected they are of high affinity and highly predictive. The
NOD mouse characteristically expresses high-affinity insulin
autoantibodies between 4 and 8 weeks of age. The antibodies
usually disappear about the time of onset of diabetes, but even
the NOR mouse (nonobese NOD-related mouse) that has insuli-
tis and rarely diabetes has the same time course of expression
of insulin autoantibodies. Thus, the factors responsible the even-
tual loss of insulin autoantibodies are not simply the loss of
islet beta cells. In the NOD mouse, deletion of the insulin 2
gene (the insulin gene expressed in thymus and islets) markedly
enhances the serum concentration of insulin autoantibodies, and
such a result is consistent with faster progression to diabetes. It
is thought (without direct proof) that the loss of thymic insulin
increases CD4+ anti-insulin T cells driving the production of auto-
antibodies by B cell lymphocytes. Insulin is derived from the
enzymatic removal of a connecting peptide (C-peptide) from
proinsulin within islet secretory granules and C-peptide is
secreted along with insulin. In general, autoantibodies react to
mature insulin, whereas specific proinsulin autoantibodies have
been difficult to demonstrate.
Conceptually similar to the NODmouse in which manipulating
insulin genes (insulin 1 versus insulin 2) alter disease, expressionImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 447
Human insulin autoantibody epitope
centered on A13 leucine
Insulin peptide B:9-23 
Figure 1. Model of Insulin Structure
On the left, human insulin autoantibody epitope
centered on A13 leucine. The gray marks the
phenylalanine of the first amino acid of the b-chain
of insulin and A13 leucine is shown in dark blue.
The light blue highlights basic regions and red
acidic regions. Shown on the right is insulin
peptide B:9-23 within the a chain helix of the
b chain of insulin.
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particular, the second-most important locus determining type 1
diabetes is the insulin gene (after the dominant effects of
the MHC). It is not variation in the insulin gene sequence but
rather a polymorphism of a variable tandem repeat 50 of the
insulin gene that is associated with risk. The long variant of the
VNTR is associated with both greater insulin message within
the thymus and protection from type 1 diabetes. In addition,
20% of patients with the rare APS-1 syndrome resulting from
a mutation of the autoimmune regulator gene (AIRE) develop
type 1 diabetes (Perheentupa, 2006; Anderson et al., 2002).
Mutations of the AIRE gene are associated with loss of expres-
sion of insulin message within the thymus (Pugliese et al.,
1997; Vafiadis et al., 1997). It is likely both of these genetic deter-
minants are acting by decreasing the small amounts of thymic
insulin important for negative selection of insulin autoreactive
T cells, and this has been mimicked in the NOD model. Insulin
specific CD4+ T cells have been demonstrated in both mouse
and human T1D. These will be discussed in more detail below.
The newest major islet autoantigen recognized by autoanti-
bodies of man is ZnT8. The ZnT8 molecule is within the mem-
brane of islet beta cell secretory granules and transports zinc
where it forms a complex with insulin. The majority of patients
developing type 1 diabetes express ZnT8 autoantibodies, and
similar to other autoantibodies, presence of ZnT8 with other
single autoantibodies (of GAD, IA-2, or insulin) greatly enhances
risk of progression. The ZnT8 molecule is polymorphic with
either an arginine or a tryptophan at position 325. This polymor-
phism is associated with risk of type 2 diabetes but probably
does not contribute to risk of type 1 diabetes. It does however
alter the epitopes recognized by autoantibodies. Patients homo-
zygous for the Trp variant can produce anti-ZnT8 autoantibodies
recognizing only the Trp variant, whereas diabetics homozygous
for the arginine variant alternatively can produce those that
specifically target the arginine variant. This is consistent with
humoral autoimmunity targeting self and not resulting from the
targeting of a molecular mimic. NOD mice do not produce anti-
ZnT8 autoantibodies and both man and mouse can respond to
ZnT8 peptides (H.W. Davidson, personal communication).448 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.Recently, chromogranin A (Chga) was
identified as the source of the antigen
for the pathogenic BDC 2.5 T cell clone
and related series of NOD-derived
T cells (Stadinski et al., 2010). The search
for this self-antigen has been driven by
the highly pathogenic nature of the BDC
2.5 and the fact that the BDC 2.5 T cell
receptor (TCR) transgenic mouse hasbeen widely used to dissect the role of T cells in the disease
process (Haskins and McDuffie, 1990; Katz et al., 1993). Earlier
work had shown that the antigen for these clones was contained
within the secretory granules of islet b cells (Bergman and
Haskins, 1994; Bergman et al., 2000) and that the clones
responded to peptide mimotopes with similar sequences
(Judkowski et al., 2001; Yoshida et al., 2002). The final identifica-
tion of Chga as the antigen came from a combination of
approaches (Stadinski et al., 2010). First, mass spectrometric
analysis of partially purified antigen suggested Chga as a strong
candidate for the source of the antigen. Second, comparison of
the sequence of a new strongly stimulatory peptide mimotope to
those of previously reported mimotopes also pointed to Chga.
Finally, islet cells from mice in which the Chga gene had been
ablatedwere shown to lack the antigen for the T cell clones. Orig-
inally identified from the chromaffin cells of the adrenal medulla,
Chga is found within the secretory vesicles of neurons and endo-
crine cells (Blaschko et al., 1967). The initial 445aa fully trans-
lated product can be differentially processed into at least 11
different biologically active species (Orr et al., 2002), a feature
which was important in identifying the naturally processed
Chga epitope that stimulates the pathogenic T cells (see below).
Thus far, autoantibodies specific for Chga have not been
described in either NOD mice or humans.
Which T Cells Are Important in T1D?
Despite the growing list of self-antigen targets, the autoimmune
destruction in man and animal models is remarkably specific,
targeting insulin producing b-cells within islets, whereas multiple
other islet cell types, producing glucagon, somatostatin, pancre-
atic polypeptide, are spared. A simple hypothesis is that T cell
autoimmunity directed toward one or even a handful of b-cell
specific antigen(s) accounts for the specific targeting, whereas
the loss of tolerance to other antigensmaymerely be a bystander
effect of b-cell destruction and subsequent antigen availability.
The question of disease relevancy has been investigated for
a number of prominent autoantigens including insulin, GAD,
IA-2, phogrin (IA-2b), and IGRP. Several strategies have been
used to address this question. For example, for determining
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‘‘recessive’’ tolerization or genetic antigen ablation strategies
can be used. Alternatively, for determining whether the antigen
is sufficient for disease development, introduction of antigen-
specific T cells into NOD mice devoid of T cells via TCR retro-
genic technology can be used. Finally, for determining whether
an antigen may contribute to disease without being either
necessary or sufficient, the ability of specific T cell clones to
accelerate the development of disease in young NOD mice can
be assessed. In both the CD4+ and CD8+ T cell compartments,
T cells that are capable of homing to the islets and causing
b-cell destruction have been isolated. Recent studies suggest
that T cell retention in islets is an antigen-specific event (Lennon
et al., 2009), yet defining the antigen specificity for all of these
islet-homing T cells is far from complete. Introduction of large
numbers of autoantigen-specific T cells through adoptive trans-
fer or transgenic and retrogenicmethods in NODmice has begun
to reveal which antigen specificities may be important for the
pathogenic process.
There is considerable evidence for the importance of insulin in
NOD T1D. For the most part, tolerization strategies with insulin
leads to the prevention or delay of disease in NOD mice (Zhang
et al., 1991; Muir et al., 1995; Coon et al., 1999; Jaeckel et al.,
2003) and removal of insulin 1, mainly expressed in the islets,
blocks disease progression (Moriyama et al., 2003). Conversely,
removal of the insulin 2 gene greatly exacerbates disease, most
likely reflecting a loss of central tolerance due to a deficiency in
thymic insulin expression (The´bault-Baumont et al., 2003;
Moriyama et al., 2003; Martin-Pagola et al., 2009). Finally, retro-
viral introduction of TCR genes from insulin reactive CD4+ T cells
into scid NODmice is sufficient to lead to insulin autoimmunity in
a significant proportion of the mice (Kobayashi et al., 2008).
The results for GAD, however, have been mixed. Induction of
recessive tolerance designed to delete pathogenic T cells rather
than induce regulatory T cells tolerization or depletion of GAD in
mice (e.g., GAD knockout) does not lead to the prevention of
disease (Tisch et al., 1993; Tian et al., 1996; Jaeckel et al.,
2003; Kash et al., 1999; Yamamoto et al., 2004). In contrast,
injections of large amounts of GAD65 intravenously resulted in
a striking decrease in the incidence of diabetes of NOD mice
(Tisch et al., 1998). In addition, injection of GAD65 in alum
decreased loss of C-peptide in man and follow-up trials are
underway (Ludvigsson et al., 2008). For the most part, GAD-
specific CD4+ T cells do not exhibit diabetogenic potential
(Arnold et al., 2004) and can even be protective (Tarbell et al.,
2002; Kim et al., 2004). However, one GAD responsive CD4+
T cell generated by peptide vaccination has been shown to be
diabetogenic (Zekzer et al., 1998). It is noteworthy that there is
very little GAD in mouse islets, whereas GAD is expressed in
all islet cells of man and is beta cell specific in the rat. A recent
study of T cell receptor retrogenic NOD mice indicates that
rather than insulitis, a major subset of anti-GAD T cell receptors
drive encephalitis as well as production of GAD65 autoanti-
bodies. Insulitis for these retrogenics only occurs if a transgene
drives GAD production in the islet beta cell (Burton et al.,
2010). This suggests GAD may be a more relevant self-antigen
target in human and rat disease than it appears to be in the
NOD mouse. Removal of other autoantigens such as IA-2
(Kubosaki et al., 2004b) and IA-2b (Kubosaki et al., 2004a) hasnot revealed these antigens as essential targets for the develop-
ment of disease.
Because of its recent identification, chromagranin A has yet to
be evaluated in tolerance or ablation experiments, and therefore
it is unknown whether this antigen is required for induction of
T1D. Retrogenic introduction of TCR genes from a number of
Chga specific CD4+ T cell clones into scid NOD mice leads to
very rapid induction of T1D. However, the failure of mice lacking
insulin 1 expression to develop T1D despite the presence of
Chga suggests that T cells specific for this antigen may become
activated and come into play only later in the disease process.
TCR retrogenic experiments have also identified additional
CD4+ T cells that are sufficient for induction of T1D in scid
NOD mice, most notably the NY4.1 and BDC 6.9 T cell clones
(Haskins and McDuffie, 1990; Verdaguer et al., 1997; Schmidt
et al., 1997; Burton et al., 2008). The antigenic target of these
T cells is not known and hence tolerance or ablation experiments
cannot be performed.
On the CD8+ T cell side T cell responses to insulin and
dystrophia myotonica kinase (DMK) are highly diabetogenic
(Wong et al., 1996; Wong et al., 1999; Graser et al., 2000;
Lieberman et al., 2004). Tolerization of NODmice to IGRP (Krish-
namurthy et al., 2008) does not prevent development of disease.
It is interesting that although the dominant natural CD8+ T cell
response directed toward the IGRP peptide 206-214 is diabeto-
genic, an exclusive response to this epitope attenuates the
development of disease (Verdaguer et al., 1997). Recent studies
suggests that the diabetogenic potential of IGRP-specific
CD8+ T cells are dependent on the loss of tolerance to insulin
(Krishnamurthy et al., 2008), and it is possible that a lack of a
response to insulin in the IGRP-specific TCR transgenic T cell-
deficient mice causes the altered disease progression.
Currently, these data leave insulin as the only self-antigen that
has consistently been shown to be essential for the diabetogenic
immune response.
Autoantigen Epitopes for Diabetogenic T Cells
Defining all the antigenic epitopes, i.e., the actual peptide that is
bound to MHC, for diabetogenic T cells is central to unraveling
the pathogenesis of T1D. Doing so will allow the production
MHC tetramers for ex vivo analysis, as well as in vivo imaging
reagents, and possibly enable efficient visualization of an
ongoing disease process in animal models, as well as humans.
The introduction of retrogenic methods to determine T cell path-
ogenicity has greatly accelerated the rate at which individual
T cells can be tested, and therefore this method is likely to
become the standard practice for evaluating diabetogenicity.
Additionally, defining themolecular targets of disease promoting
T cells will help in designing antigen-specific therapies that can
modulate the autoimmune response and may eventually prevent
the development disease.
Given the initial discovery of insulin autoantibodies, multiple
investigators have characterized T cells reacting with insulin,
proinsulin, and preproinsulin peptides (Congia et al., 1998).
Both CD8+ and CD4+ T cell reactivity is well defined for man
and the NOD mouse (Petrich de Marquesini et al., 2008; Wong
et al., 2009; Skowera et al., 2008; Pinkse et al., 2006; Alleva
et al., 2001; Kent et al., 2005; Hassainya et al., 2005; Durinovic-
Bello´ et al., 2010). For man, studies are limited to evaluation ofImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 449
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nodes (Kent et al., 2005). Reported CD4 T cell epitopes include
insulin peptide B:9-23 (Alleva et al., 2001) identical in sequence
to the insulin 2B:9-23 peptide targeted byNODmouse T lympho-
cytes, insulin A:1-15 recognized at high concentrations by clones
derived from pancreatic lymph nodes (Kent et al., 2005), and
a proinsulin DR4 restricted peptide (C19-A3) being evaluated in
clinical trials as a subcutaneous injection in patients with new-
onset diabetes(Thrower et al., 2009). Responses to a proinsulin
(PI) 76-90 (SLQPLALEGSLQKRG) epitope are influenced by
a polymorphic repeat sequence 50 of the insulin gene that is
associated with diabetes risk (Durinovic-Bello´ et al., 2010).
Prominent CD8+ T cell epitopes include a preproinsulin signal
peptide (Skowera et al., 2008) and insulin B10-18, B18-27, and
A12-20 (Velthuis et al., 2010; Pinkse et al., 2006). Peakman
and coworkers have demonstrated enhanced killing of human
islet beta cells cultured in high glucose by CD8+ T cells recog-
nizing the preproinsulin signal peptide (Skowera et al., 2008).
There has been one major clinical trial of an insulin peptide
(altered peptide ligand of insulin B:9-23 [NBI-6024]) that failed
to alter loss of beta cell function in new-onset patients (Walter
et al., 2009).
Aswould be expected the immune response to insulin is better
characterized for the NOD mouse model, with studies of T cells
isolated directly from islets and the ability to test generation of
disease with transfer of clones or creation of T cell receptor
transgenic and retrogenic models (Daniel et al., 1995; Jasinski
et al., 2006; Burton et al., 2008). Again both CD4+ and CD8+
T cells target insulin peptides. In addition, gamma delta cells
in the absence of antigen-presenting cells can target insulin
peptide B:9-23 (Zhang et al., 2010), and insulin-induced gamma
delta T cells has been shown to prevent diabetes (Ha¨nninen and
Harrison, 2000). Perhaps the best-studied epitopes are within
the insulin B:9-23 peptide (Figure 1, alpha helix) (Wegmann
et al., 1994). Wong and coworkers defined a CD8+ T cell clone
(G9C8) that recognizes insulin peptide B:15-23 (Wong et al.,
1999). T cells reacting with a tetramer directed at this peptide
are prominent in early lesions of NOD mice, but less prominent
as insulitis proceeds. A T cell receptor transgenic of the G9C8
clone developed insulitis, whereas diabetes ensued only after
immunization and activation of the CD8+ T cells (Wong et al.,
2009). Multiple CD4+ T cell clones reacting with insulin B:9-23
peptides have been characterized with several T cell receptor
transgenics and retrogenics studied. However different proper-
ties of these insulin B:9-23-specific clones have been reported.
In this regard, the 2H6 T cell clone both as a clone and as a
transgenic recognizes this peptide and prevents type 1 diabetes
associated with the production of large amounts of TGF-b
(Du et al., 2006; Zekzer et al., 1997), whereas the BDC 12-4.1
clone and T cell receptor transgenic are diabetogenic (Jasinski
et al., 2006). It thus appears that pathogenicity reflects specific
T cell receptor sequences despite targeting of similar peptides.
The targeting of proinsulin (Jaeckel et al., 2004; French et al.,
1997) and the native B:9-23 peptide appear to be essential for
the development of diabetes in NOD mice (Nakayama et al.,
2005). NOD mice lacking endogenous insulin genes and only
expressing insulin with the B16 tyrosine mutated to alanine fail
to develop diabetes and expression of insulin autoantibodies
is markedly suppressed. The immune response to insulin is450 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.‘‘upstream’’ of the immune response to IGRP. Whereas class II
promoter-driven expression of IGRP fails to influence progres-
sion to diabetes, similar promoter-driven proinsulin prevents
both the appearance of IGRP autoreactivity as well as progres-
sion to diabetes (Krishnamurthy et al., 2006). In addition, even
for a mouse bearing transgenic TCRs specific for IGRP, the
immune response to proinsulin remains important for pathoge-
nicity (Krishnamurthy et al., 2008).
Surprisingly despite the longstanding knowledge that insulin-
reactive diabetogenic T cells recognize the B:9-23 insulin
peptide, there has been considerable difficulty in the identifica-
tion of the relevant epitope(s) for the T cells within this peptide,
leading to the idea that this peptide may bind to the MHC class
II molecule I-Ag7 and be recognized by T cells in more than one
way. Unlike MHC I peptide epitopes, peptides bind to MHC II
in an extended polyproline-like conformation with the ends of
the peptide often extending beyond the ends of the peptide
binding groove. Thus, the peptide is free to bind in multiple
‘‘frames’’ or ‘‘registers,’’ limited only by the placement of amino
acids at four fixed positions within the groove (p1, p4, p6, and p9)
that are compatible with corresponding polymorphic amino acid
side chain-binding pockets. For conventional peptide, antigens
usually the need to match peptide amino acid side chains to
the pockets leads to one of the registers being most favored
and recognized by themajority of responding T cells. For autoan-
tigens, the situation may not be so straightforward, given that
the strongest binding registers may trigger negative selection
in the thymus. To examine the potential for insulin B:9-23 peptide
to bind MHC II in multiple registers, Levisetti et al. (2007) per-
formed an extensive truncational and mutation analysis of this
peptide examining both I-Ag7 binding and recognition by a large
set of insulin specific T cell clones. They concluded that the
peptide bound to I-Ag7 in either of two adjacent registers and
that T cells recognized one or the other of the two complexes.
Of note, a recent manuscript by the same group provides
convincing data that the B:9-23 peptides are generated within
islets, and a subset of the autoreactive T cells cannot recognize
the peptide when insulin is processed by antigen-presenting
cells, but require the peptide potentially to be preformed in islet
b-cell secretory granules (Mohan et al., 2010). In addition to
studies of the binding of insulin peptides to I-Ag7, we have
sequenced T cell receptors of clones recognizing the B:9-23
peptide (Abiru et al., 2000). The majority of the clones, isolated
from islets of NOD mice by Dylan and Wegman, that recognized
insulin peptide B:9-23 utilized the genome-encoded T cell
receptor TRAV-5D-4*04 Valpha sequence, despite very different
CDR3 (complementarity determining region) sequences and no
conservation of the beta chain of the T cell receptor (Simone
et al., 1997). This has led to the hypothesis that a series of rela-
tively nonstringent T cell receptors with this Valpha element
targeting the insulin peptide B:9-23 are central to the pathogen-
esis of islet autoimmunity of NOD mice (Kobayashi et al., 2008;
Nakayama et al., 2007; Lipes et al., 1993). Transgenics and ret-
rogenics with this Valpha element have now been studied
(Kobayashi et al., 2008 andM. Nakayama, personal communica-
tion) with the observation that this Valpha can entrain in vivo
anti-insulin autoimmunity as well as diabetes (Zhang et al.,
2009). The T cell repertoire of NOD mice can be markedly per-
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Figure 2. Common BDC2.5 Mimotope Motif
The motif (larger letters) containing mimotopes,
but not the corresponding Chga peptide stimu-
lates the BDC2.5 T cell clone (Stadinski et al.,
2010).
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Perspectivetransgenic introduction of irrelevant T cell receptor Vbeta chain
(Lipes et al., 1993). This may relate to the dominance of the
TRAV-5D-4 element in driving insulin autoimmunity. Although
the TRAV-5D-4 element is ‘‘sufficient’’ for NOD islet autoimmu-
nity, it has not yet been tested as to whether it is essential
(e.g., targeted gene ablation).
As discussed above, Chga was recently identified as the
antigenic source of the highly pathogenic BDC-2.5 clone and
other related T cell clones (Stadinski et al., 2010). One of the
properties of Chga that help pinpoint it as the antigen source
for BDC-2.5 was the presence of a five amino acid motif in the
sequence (WXRM[EorD]) that was shared with BDC-2.5-stimu-
lating peptide mimotopes identified in various libraries by three
different groups (Judkowski et al., 2001; Yoshida et al., 2002;
Stadinski et al., 2010) (Figure 2). In the design of these libraries,
this motif would fill positions p5-p9 in the peptide binding
groove. However, the corresponding peptide from Chga surpris-
ingly failed to stimulate BDC-2.5 or any of the other T cell clones.
However, all of the clones were stimulated by a peptide, WE14,
naturally processed from Chga by a furin-like protease, which
placed the important motif at its N rather than C terminus
(Figure 3).
This result suggested an unusual binding mode for the epitope
for these T cells that only partially filled the peptide-binding
groove, leaving positions prior to p5 empty and extending far
beyond the peptide-biding groove at its C terminus. Further-
more, they suggested that Chga amino acids N-terminal to
WE14 were inhibitory for the response. In exploring this idea,
various Chga peptides were directly compared to one of the
BDC-2.5 mimotopes for T cell stimulation and binding to I-Ag7
(Stadinski et al., 2010). Some of the data from this study are
summarized in Figure 3. The library mimotope that strongly
bound to I-Ag7 stimulated the BDC-2.5 clone. The WE14 peptide
also bound to I-Ag7 and stimulated BDC-2.5, but less strongly.
The Chga peptide designed to fill the usual peptide groove
neither bound to I-Ag7 nor stimulated BDC-2.5. Meanwhile, trun-
cation of the portion of WE14 C-terminal to the shared motif
produced a peptide inactive in both assays. Finally, adding
back four Chga amino acids to the N-terminus of WE-14 had
no effect on binding to I-Ag7, but eliminated BDC-2.5 recognition.
These data would suggest that theChga-specific T cells can only
recognize a peptide that is precisely processed from Chga and
presented by I-Ag7 in a very unusual way. A long C-terminal
extension of the peptide from the peptide biding groove is essen-Immunitytial for I-Ag7 binding in some unknown
way and the placement of Chga amino
acids in the p1-p4 position of the binding
groove prevents T cell recognition. This
same study showed that the WE-14
peptide is less potent as an antigen for
BDC-2.5 than islet antigen extracts, sug-
gesting that a better stimulating epitopeis present in the islets, thereby raising the possibility of a natural
modification of theWE-14 peptide to increase its affinity for I-Ag7
or for the TCR. Current studies are already underway to discrim-
inate between these two possibilities and provide an answer that
will surely be intriguing.
Is Evading Central Tolerance an Epitope Intrinsic
Property?
During T cell development in the thymus, self-reactive CD4+
T cells are eliminated when its TCR strongly engages an MHC
II complex containing self-antigen peptide (Anderson et al.,
1996). Therefore, central tolerance represents a primary barrier
to autoimmunity that disease-promoting self-reactive T cells
must overcome prior to carrying out a pathogenic response
in the periphery. It has been suggested that disease-promoting
MHC II alleles form low-affinity interactions with the peptides
they present and that this general deficiency in presentation
allows autoreactive T cells to escape central tolerance (Carra-
sco-Marin et al., 1996). However, peptide-binding studies
suggest that this may not be the case, as these disease-
promoting MHC II alleles can form stable interactions with pre-
sented peptide ligands (Yu et al., 2000). Additionally, efficient
deletion of the BDC 2.5 transgenic T cells is observed on the
B6.H2g7 background with a mimotope peptide that contains
a favorable binding register (Judkowski et al., 2001), suggesting
that I-Ag7 is capable of mediating sufficient negative selection
(Zucchelli et al., 2005; Judkowski et al., 2001).
The recent findings with the WE-14 epitope and the insulin
B:9-23 peptide suggest a different perspective. Although the
recognized epitopes of Chga and insulin do bind I-Ag7 with very
low affinity, this is not due to a general defect in peptide binding.
Rather, the deficiency in negative selection may be rooted in
the unique way in which these peptides interact with the
disease-promoting MHC II molecule as well as islet-specific
production of relevant peptides. Special peptide processing
requirements, failure to fill the peptide-binding groove, com-
peting overlapping registers, or registers that are unfavored
by the MHC II polymorphic peptide-binding pockets all can
certainly decrease presentation of particular epitopes in the
thymus and increase the ability of T cells targeting these epitopes
to escape negative selection. Thus, itmaybe themanner inwhich
epitopes interact with the MHC II molecule that determines
whether or not diabetogenic T cells are able to efficiently evade














































































Figure 3. Chromagranin A Peptide Motifs
Relative ability of various motif containing Chga peptides to stimulate the BDC 2.5 T cell clone and bind to I-Ag7, compared to a peptide mimotope selected for
strong stimulation of BDC 2.5 (Stadinski et al., 2010).
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Genetic susceptibility to T1D in humans, NOD mice, and the BB
(biobreeding) rat is largely driven by the MHC II locus (Hattori
et al., 1986; Davies et al., 1994; Prochazka et al., 1987; Colle
et al., 1981), and there is a distinctive correlation to high-risk
and protective MHC II alleles across all three species. Yet the
reason that certain MHC II alleles increase disease susceptibility
remains unknown. In T1D, the most enticing finding concerning
MHC II has been the identification of a non-Asp polymorphism
at position 57 of the MHC II b-chain, common to several
disease-promoting alleles (Todd et al., 1987; Todd et al., 1988).
Structural studies have shown that this mutation causes the
loss of salt bridge to Arg76 on MHC II a chain and chemically
alters the p9 peptide-binding pocket to include a specificity for
acidic residues that is unique to these alleles (Corper et al.,
2000; Lee et al., 2001). The most straightforward hypothesis
from these studies suggests that disease-promoting MHC II
alleles selectively present essential islet antigen epitopes that
are not presented by other non-disease-promoting alleles (Suri
et al., 2002).
Recognition of insulin by specific T cell receptors (e.g., anti-
B:9-23 T cells with TRAV-5D-4 containing alpha chains) in an
unfavorable binding register could increase the chances that
such insulin-responsive CD4+ T cells would escape central toler-
ance because of decreased presence of their cognate MHC-
peptide complex. Given that a decrease in central tolerance
to insulin appears to be essential for the development of T1D
in the NOD mouse (Jaeckel et al., 2003; French et al., 1997),
then recognition of an unfavorable binding register would help
to generate the pool peripheral pathogenic T cells required to
cause disease.
Are There Common MHC II Binding ‘‘Rules’’
for Unconventional Autoimmune T Cell Epitopes?
The MHC II is an important component of disease susceptibility,
not only in T1D but in many other autoimmune diseases as well
(Fernando et al., 2008). It is possible that the unique MHC II
binding attributes of the WE-14 and insulin epitopes highlight
specific ‘‘rules’’ for epitopes of many pathogenic self-reactive452 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.CD4+ T cells. In another animal model of autoimmunity, experi-
mental autoimmune encephalomyelitis (EAE), a pathogenic
T cell epitope incorporates strikingly similar strategies when
binding the I-Au MHC II molecule (Gautam et al., 1992). EAE
can be induced by the immunization of I-Au expressing PL/J
mice with myelin basic protein (MBP) (Fritz et al., 1983) and
T cell clones responsive to an N-terminal fragment of MBP are
known to be highly pathogenic (Zamvil et al., 1985). Peptide
binding and structural work has revealed that the epitope for
these pathogenic T cells is bound to IAu, leaving the p1–p3 posi-
tions of the peptide groove empty, and utilizes an unfavorable
anchor residue at p6 (Lee et al., 1998; He et al., 2002). The obser-
vation that theWE-14 epitopemost likely leaves the I-Ag7 binding
groove empty from p1 to p4 and that the insulin B:12-23 epitope
binds in a register utilizing a highly unfavored anchor residue
(Stadinski et al., 2010; B.S., unpublished data) suggests that
these odd binding strategies may be the rules for how epitopes
of pathogenic self-reactive T cells interact with MHC II mole-
cules. In EAE, the ‘‘odd’’ MHC II binding strategy gives the
epitope a weak binding affinity for I-Au and helps the pathogenic
T cells evade central tolerance (Seamons et al., 2003). This
further suggests that central tolerance is themain barrier to auto-
immunity and that critical self-antigen epitopes interact with
disease-promoting MHC II molecules in unconventional ways
to promote the generation of pathogenic CD4+ T cells.
Implications
The fundamental determinants of autoimmune diabetes at
a species level are likely to be genome encoded sequences of
the MHC II and TCR complexes essential for presentation and
recognition of specific islet antigenic peptides to CD4+ T cell
lymphocytes. High probability for loss of tolerance to specific
islet peptides appear to depend upon the manner in which
specific peptides bind to class II-presenting molecules and are
recognized by T cell receptors. Poor peptide binding due to
only partially filling the MHC groove or using unfavorable regis-
ters probably sets the stage for escape of autoreactive T cells
from the thymus. In the periphery, an abundance of particular
self-antigens, such as insulin in the islets, or modification of
Immunity
Perspectivethe antigen, as may be the case for Chga, should allow for suffi-
cient presentation of odd binding epitopes to autoreactive
T cells. Additionally, for the insulin B:9-23 peptide of the NOD
mouse, a relatively nonstringent family of T cell receptors may
be able to react with this dominant epitope by virtue of having
the genome encoded TRAV5D-4*04 receptor element, with no
apparent conservation of CDR3 or the T cell receptor beta chain.
Although germline-encoded sequences may set the stage for
islet autoimmunity, they do not fully determinewhich individual of
a species will develop diabetes. Other genes and environmental
factors determining the potential for loss of tolerance given the
presence of autoreactive T cell lymphocytes determine indi-
vidual risk. In man, mutations and polymorphisms controlling
expression of minute amounts of insulin within the thymus influ-
ence risk, and this is readily modeled in the NOD mouse. Muta-
tions that eliminate regulatory T cell lymphocytes (FOXP3-IPEX
syndrome) and T cell receptor signaling (PTPN22) as well as
multiple common polymorphisms contribute further.
Concluding Remarks
The NOD mouse has a single class II molecule I-Ag7, and
although humans developing type 1 diabetes have characteristic
HLA genotypes, multiple genotypes are represented among
patients, and there is evidence that the percentage of DR3 and
DR4 highest-risk heterozygous genotype has decreased as
a percentage of diabetics over the past several decades. This
suggests that the penetrance of lower-risk genotypes has
increased dramatically, as the incidence of type 1 diabetes is
increasing. These rapid changes are almost certainly due to
unknown changes in the environment. Our knowledge of trimo-
lecular complexes underlying targeting of islet autoantigens in
man is woefully inadequate. Recent development of a program
(nPOD) to obtain pancreas from cadaveric donors with type 1
diabetes will hopefully allow the characterization of T cells
and T cell receptors similar to what is being accomplished
for animal models. If specific molecular interactions resulting
from genome-encoded sequences of MHC II and TCR underlie
susceptibility to autoimmunity, targeting ‘‘pathogenic’’ com-
plexes may provide specific disease prevention. Animal models
are now available to directly test this hypothesis with the impor-
tant caveat that even if a single autoantigen is primary, once
epitope spreading occurs, reactivity of T cells targeting multiple
determinants may need to be controlled. Direct testing of this
and other hypotheses are now possible, and we hope this will
help guide the development of safe preventive therapy.
Although it is likely that specific response to insulin is the initial
trigger in the NODmouse, this may not be the case in humans. It
is possible that the different antigens can serve as essential initi-
ating epitopes dictated by which combinations of MHC II alleles
are present in the individual patient. Understanding how all self-
antigens of the diabetogenic immune response are targetedmay
provide insight to understand the multiple ways in which islet
autoimmunity can be triggered and propagated in humans.
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